Investigation Launched by Pomerantz LLP into Anika Therapeutics, Inc.
Pomerantz LLP has launched an investigation into potential securities violations involving Anika Therapeutics, Inc. (NASDAQ: ANIK), on behalf of its investors. Investors are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980.
Focus of the Probe
The probe centers on whether Anika and its executives engaged in fraudulent or unlawful activities related to the company's recent disclosures.
Recent Company Announcements and Stock Impact
On July 30, 2025, Anika announced preliminary results from a U.S. clinical trial of Hyalofast, a biodegradable scaffold combined with autologous bone marrow aspirate for cartilage repair. The company reported consistent improvements in patient outcomes but noted that the study did not meet its primary endpoints. Factors such as higher dropout rates in the microfracture group and COVID-related missed visits may have affected data integrity.
Following this announcement, Anika's stock price declined by $3.06, or approximately 27.42%, closing at $8.10 per share.
About Pomerantz LLP
Pom...